Antrafenine

Summary

Antrafenine (CHEMBL345524) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 588.5 Da · C30H26F6N4O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL345524
Name	Antrafenine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	68723
Molecular formula	C30H26F6N4O2
Molecular weight	588.5
InChIKey	NWGGKKGAFZIVBJ-UHFFFAOYSA-N

SMILES: C1CN(CCN1CCOC(=O)C2=CC=CC=C2NC3=C4C=CC(=CC4=NC=C3)C(F)(F)F)C5=CC=CC(=C5)C(F)(F)F

IUPAC name: 2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl 2-[[7-(trifluoromethyl)quinolin-4-yl]amino]benzoate

Also known as: Antrafenina, Antrafenine, ANTRAFENINE

Patent coverage: 506 distinct patent families (1,723 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,718 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).